Nov 2, 2016 8:03 am EDT Abeona Therapeutics Announces JAMA Publication of Positive Phase 1 Study Results for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
Nov 1, 2016 10:23 am EDT Abeona Therapeutics Inc. Announces Closing of its Underwritten Offering of Common Stock
Oct 25, 2016 7:45 am EDT Abeona Therapeutics Announces Fast Track Designation from FDA for ABO-102 in Sanfilippo Syndrome Type A
Oct 20, 2016 7:43 am EDT Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at Orphan Drugs & Rare Disease Conference, London UK
Oct 18, 2016 7:45 am EDT Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-102 Gene Therapy in Sanfilippo Syndrome Type A
Oct 14, 2016 7:03 am EDT Abeona Therapeutics to Present Top-Line Data of Low-Dose Cohort for ABO-102 in Phase 1/2 Clinical Trial for MPS IIIA Patients at Upcoming Orphan Drugs and Rare Disease Congress October 19-20th in London, UK
Oct 7, 2016 9:19 am EDT Abeona Therapeutics Announces Publication of Preclinical Data Supporting Clinical Translation of Juvenile Batten Disease Gene Therapy
Oct 5, 2016 7:03 am EDT Abeona Therapeutics Announces Data Safety Monitoring Board Approves ABO-102 Dose Escalation for Second Cohort in Phase 1/2 Clinical Trial for Sanfilippo Syndrome Type A
